An hypothetical risk of SARS-CoV-2 airborne transmission through nebulization was suggested based on a potential contamination of the fugitive aerosol emitted in the environment during the procedure. The aim of this study was to verify this risk from the fugitive aerosol emitted by COVID-19 patients during one nebulization session.
In this cohort study, COVID-19 patients treated with nebulization were recruited at their admission to the hospital.Patients had to perform a nebulization session while a BioSampler® and a pump were used to vacuum the fugitive aerosol and collect it for SARS-CoV-2 RNA detection.

Ten consecutive patients hospitalized with COVID-19 were recruited. The median viral load was 6.5x10^6 copies/mL. Two out of the ten samples from the fugitive aerosol collected were positive to SARS-CoV-2.
The risk of SARS-CoV-2 airborne contamination through the nebulization has been verified.